Literature DB >> 22956587

T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination.

Taylor H Schreiber1, Dietlinde Wolf, Maria Bodero, Louis Gonzalez, Eckhard R Podack.   

Abstract

TNFR superfamily (TNFRSF)4 (OX40, CD134) and TNFRSF25 are costimulatory receptors that influence CD4(+) and CD8(+) T cell responses to cognate Ag. Independently, these receptors have been described to stimulate overlapping functions, including enhanced proliferation and activation for both regulatory T cells (CD4(+)Foxp3(+); Tregs) and conventional T cells (CD4(+)Foxp3(-) or CD8(+)Foxp3(-); Tconvs). To determine the relative functionality of TNFRSF4 and TNFRSF25 in T cell immunity, the activity of TNFRSF4 and TNFRS25 agonistic Abs was compared in the context of both traditional protein/adjuvant (OVA/aluminum hydroxide) and CD8(+)-specific heat shock protein-based (gp96-Ig) vaccine approaches. These studies demonstrate that both TNFRSF4 and TNFRSF25 independently and additively costimulate vaccine-induced CD8(+) T cell proliferation following both primary and secondary Ag challenge. In contrast, the activities of TNFRSF4 and TNFRSF25 were observed to be divergent in the costimulation of CD4(+) T cell immunity. TNFRSF4 agonists were potent costimulators of OVA/aluminum hydroxide-induced CD4(+) Tconv proliferation, but they only weakly costimulated Treg proliferation and IgG2a production, whereas TNFRSF25 agonists were strong costimulators of Treg proliferation, producers of IgG1, IgG2a, and IgG2b, and weak costimulators of CD4(+) Tconv proliferation. Interestingly, Ag-specific cellular and humoral responses were uncoupled upon secondary immunization, which was dramatically affected by the presence of TNFRSF4 or TNFRSF25 costimulation. These studies highlight the overlapping but nonredundant activities of TNFRSF4 and TNFRSF25 in T cell immunity, which may guide the application of receptor agonistic agents as vaccine adjuvants for infectious disease and tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956587      PMCID: PMC3449097          DOI: 10.4049/jimmunol.1200597

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  The role of TNFRSF25:TNFSF15 in disease… and health?

Authors:  Taylor H Schreiber; Dietlinde Wolf; Eckhard R Podack
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 2.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

3.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 4.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

5.  Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection.

Authors:  K Yamazaki; T Nguyen; E R Podack
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

6.  Triggering of TNFRSF25 promotes CD8⁺ T-cell responses and anti-tumor immunity.

Authors:  Tomasz J Slebioda; Tania F Rowley; John R Ferdinand; Jane E Willoughby; Sarah L Buchan; Vadim Y Taraban; Aymen Al-Shamkhani
Journal:  Eur J Immunol       Date:  2011-08-04       Impact factor: 5.532

7.  The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

Authors:  I Gramaglia; A Jember; S D Pippig; A D Weinberg; N Killeen; M Croft
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

Review 8.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

9.  Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity.

Authors:  Tracy L Flach; Gilbert Ng; Aswin Hari; Melanie D Desrosiers; Ping Zhang; Sandra M Ward; Mark E Seamone; Akosua Vilaysane; Ashley D Mucsi; Yin Fong; Elmar Prenner; Chang Chun Ling; Jurg Tschopp; Daniel A Muruve; Matthias W Amrein; Yan Shi
Journal:  Nat Med       Date:  2011-03-13       Impact factor: 53.440

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  17 in total

1.  Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Authors:  Jan Tavernier; Sarah Gerlo; Bram Van Den Eeckhout; Lien Van Hoecke; Elianne Burg; Sandra Van Lint; Frank Peelman; Niko Kley; Gilles Uzé; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2020-07-23       Impact factor: 7.344

2.  Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.

Authors:  William T Curry; Ramana Gorrepati; Matthias Piesche; Tetsuro Sasada; Pankaj Agarwalla; Pamela S Jones; Elizabeth R Gerstner; Alexandra J Golby; Tracy T Batchelor; Patrick Y Wen; Martin C Mihm; Glenn Dranoff
Journal:  Clin Cancer Res       Date:  2016-02-12       Impact factor: 12.531

Review 3.  Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.

Authors:  Natasa Strbo; Arlene Garcia-Soto; Taylor H Schreiber; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

4.  Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy.

Authors:  Doris Lambracht-Washington; Roger N Rosenberg
Journal:  J Neuroimmunol       Date:  2014-12-10       Impact factor: 3.478

5.  Promising prognostic value of Transglutaminase type 2 and its correlation with tumor-infiltrating immune cells in skin cutaneous melanoma.

Authors:  Silvia Muccioli; Roberto Ciaccio; Valentina Brillo; Luigi Leanza
Journal:  Cell Death Discov       Date:  2022-06-20

Review 6.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

7.  Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.

Authors:  Nusrat Jahan; Hammad Talat; William T Curry
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

Review 8.  Immunobiology of TNFSF15 and TNFRSF25.

Authors:  Taylor H Schreiber; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 9.  Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review).

Authors:  Yunhong Yu; Peng Jiang; Pan Sun; Na Su; Fangzhao Lin
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

10.  TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses.

Authors:  Bruna Oriol-Tordera; Alex Olvera; Clara Duran-Castells; Anuska Llano; Beatriz Mothe; Marta Massanella; Judith Dalmau; Carmela Ganoza; Jorge Sanchez; Maria Luz Calle; Bonaventura Clotet; Javier Martinez-Picado; Eugènia Negredo; Julià Blanco; Dennis Hartigan-O'Connor; Christian Brander; Marta Ruiz-Riol
Journal:  J Immunol       Date:  2020-11-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.